Increased neutrophil-endothelial adhesion induced by placental factors is mediated by platelet-activating factor in preeclampsia
- PMID: 10376269
- DOI: 10.1016/s1071-5576(99)00004-0
Increased neutrophil-endothelial adhesion induced by placental factors is mediated by platelet-activating factor in preeclampsia
Abstract
Objective: Endothelial cell activation or dysfunction and neutrophil-endothelial cell adhesion have been suggested to be important in the pathophysiology of preeclampsia. However, the mechanisms that underlie the alteration of endothelial cell function in preeclampsia are unknown. Placenta from preeclamptic pregnancies produces mediators and autacoids, which may be released into the maternal circulation and modulate endothelial function. In this study, the effect of placental factor(s) on neutrophil-endothelial adhesion and the possible role of platelet-activating factor (PAF) in mediating the response have been examined.
Methods: Endothelial cells were isolated from human umbilical veins (HUVECs) from normal pregnancies. Confluent primary passage HUVECs were exposed to conditioned medium derived from normal and preeclamptic placental tissue cultures, with unconditioned medium as a control. Placental-conditioned medium was prepared by incubation of placental whole villous tissue in Dulbecco's Modified Eagle's Medium (DMEM) for 48 hours. Neutrophil-endothelial adhesion assays were performed to evaluate placental factors in mediating neutrophil-endothelial adhesion, and a PAF-3H scintillation proximity assay (SPA) system was used to determine endothelial PAF production. The PAF-receptor antagonist WEB 2086 was used to block placental factor-mediated increased neutrophil-endothelial adhesion induced by conditioned medium derived from preeclamptic placenta.
Results: Neutrophils were significantly more adherent to HUVECs treated with conditioned medium from preeclamptic placentas (28.44 +/- 2.47%) than to HUVECs treated with conditioned medium from normal placentas (18.95 +/- 1.57%) or with unconditioned medium (14.60 +/- 1.29%, P < .01). Also, HUVECs exposed to preeclamptic placental-conditioned medium produced more PAF than the cells exposed to normal conditioned medium and unconditioned medium, 416.18 +/- 17.14 pg/1 x 10(7) cells versus 330.90 +/- 35.70 and 296.43 +/- 44.40 pg/1 x 10(7) cells, P < .05, respectively. The PAF receptor antagonist WEB 2086 completely blocked increased neutrophil-endothelial adhesion induced by preeclamptic placental-conditioned medium (13.24 +/- 0.81% versus 31.31 +/- 4.75%, P < .01).
Conclusion: In preeclampsia, the placenta releases one or more factors promoting neutrophil-endothelial adhesion. The increased neutrophil-endothelial adhesion thereby induced is a PAF-mediated event. It is suggested that if preeclamptic placentas release toxic factors into the maternal circulation in vivo, these factors may contribute to the altered vascular endothelial cell function in preeclampsia.
Similar articles
-
Activation of endothelial cells in preeclampsia: increased neutrophil-endothelial adhesion correlates with up-regulation of adhesion molecule P-selectin in human umbilical vein endothelial cells isolated from preeclampsia.J Soc Gynecol Investig. 1998 Sep-Oct;5(5):237-43. doi: 10.1016/s1071-5576(98)00023-9. J Soc Gynecol Investig. 1998. PMID: 9773398
-
PAF levels and PAF-AH activities in placentas from normal and preeclamptic pregnancies.Placenta. 2006 Jun-Jul;27(6-7):744-9. doi: 10.1016/j.placenta.2005.06.005. Epub 2005 Aug 24. Placenta. 2006. PMID: 16122793
-
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.Am J Obstet Gynecol. 2016 Mar;214(3):356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019. Epub 2015 Dec 22. Am J Obstet Gynecol. 2016. PMID: 26721779
-
Regulation of platelet-activating factor (PAF) synthesis and PAF-mediated neutrophil adhesion to endothelial cells activated by thrombin.Semin Thromb Hemost. 1992 Jan;18(1):126-34. doi: 10.1055/s-2007-1002417. Semin Thromb Hemost. 1992. PMID: 1315452 Review. No abstract available.
-
Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?Am J Obstet Gynecol. 2022 Feb;226(2S):S945-S953. doi: 10.1016/j.ajog.2021.11.1367. Am J Obstet Gynecol. 2022. PMID: 35177224 Free PMC article. Review.
Cited by
-
Obesity Correlates with Chronic Inflammation of the Innate Immune System in Preeclampsia and HELLP Syndrome during Pregnancy.Biomedicines. 2023 Oct 20;11(10):2851. doi: 10.3390/biomedicines11102851. Biomedicines. 2023. PMID: 37893224 Free PMC article.
-
Up-regulation of miR-203 expression induces endothelial inflammatory response: Potential role in preeclampsia.Am J Reprod Immunol. 2016 Dec;76(6):482-490. doi: 10.1111/aji.12589. Epub 2016 Oct 18. Am J Reprod Immunol. 2016. PMID: 27753461 Free PMC article.
-
Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia.Reprod Sci. 2008 Nov;15(9):932-8. doi: 10.1177/1933719108322432. Reprod Sci. 2008. PMID: 19050326 Free PMC article.
-
Placenta-derived chymotrypsin-like protease (CLP) disturbs endothelial junctional structure in preeclampsia.Reprod Sci. 2009 May;16(5):479-88. doi: 10.1177/1933719108329818. Epub 2009 Jan 6. Reprod Sci. 2009. PMID: 19126871 Free PMC article.
-
Neonatal Thrombocytopenia as a Consequence of Maternal Preeclampsia.AJP Rep. 2016 Mar;6(1):e42-7. doi: 10.1055/s-0035-1565923. Epub 2015 Oct 28. AJP Rep. 2016. PMID: 26929869 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources